Web Reference: Jul 9, 2019 · Iscalimab is a fully human, CD40 pathway blocking, nondepleting monoclonal antibody being developed as an immunosuppressive agent. We describe a first-in-human, randomized, double-blind, placebo-controlled study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of iscalimab in healthy subjects and rheumatoid arthritis patients. Healthy subjects (n = 56) received ... Sep 12, 2019 · Iscalimab (CFZ533) is a fully human, pathway blocking, and nondepleting (Fc-silent) anti-CD40 monoclonal-Ab (22). It inhibits CD154-induced activation of human leukocyte activation in vitro. In vivo, iscalimab blocked primary and recall T-cell–dependent Ab responses in nonhuman primates and abrogated GC formation without depleting peripheral blood B cells (22). Iscalimab prolonged the renal ... Iscalimab is a fully human, CD40 pathway blocking, nondepleting monoclonal antibody being developed as an immunosuppressive agent. We describe a first‐in‐human, randomized, double‐blind, placebo‐controlled study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of iscalimab in healthy subjects and rheumatoid arthritis patients. Healthy subjects (n = 56 ...
YouTube Excerpt: 00:00
Net Worth Profile Overview
How Much Will I Get Net Worth 2026: Salary, Income & Wealth Net Worth & Biography
Estimated Worth: $62M - $68M
Salary & Income Sources
Career Highlights & Achievements
Assets, Properties & Investments
This section covers known assets, real estate holdings, luxury vehicles, and investment portfolios. Data is compiled from public records, financial disclosures, and verified media reports.
Last Updated: April 1, 2026
Net Worth Outlook & Future Earnings
Disclaimer: Disclaimer: Net Worth estimates are based on publicly available data, media reports, and financial analysis. Actual numbers may vary.